These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36672405)

  • 21. Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
    Passacantilli I; Panzeri V; Terracciano F; Delle Fave G; Sette C; Capurso G
    Oncol Rep; 2018 Apr; 39(4):1984-1990. PubMed ID: 29393478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
    Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
    J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC.
    Brown M; Zhang W; Yan D; Kenath R; Le L; Wang H; Delitto D; Ostrov D; Robertson K; Liu C; Pham K
    PLoS One; 2020; 15(1):e0226917. PubMed ID: 31929540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.
    Lu T; Tang J; Shrestha B; Heath BR; Hong L; Lei YL; Ljungman M; Neamati N
    Theranostics; 2020; 10(15):6959-6976. PubMed ID: 32550915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.
    Long KB; Tooker G; Tooker E; Luque SL; Lee JW; Pan X; Beatty GL
    Mol Cancer Ther; 2017 Sep; 16(9):1898-1908. PubMed ID: 28611107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Azmi AS; Khan HY; Muqbil I; Aboukameel A; Neggers JE; Daelemans D; Mahipal A; Dyson G; Kamgar M; Al-Hallak MN; Tesfaye A; Kim S; Shidham V; M Mohammad R; Philip PA
    Clin Cancer Res; 2020 Mar; 26(6):1338-1348. PubMed ID: 31831564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
    Wu X; Cao Y; Xiao H; Li C; Lin J
    Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista.
    Shi W; Yan D; Zhao C; Xiao M; Wang Y; Ma H; Liu T; Qin H; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
    Biochem Biophys Res Commun; 2017 Sep; 491(1):159-165. PubMed ID: 28711499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gp130-Mediated STAT3 Activation Contributes to the Aggressiveness of Pancreatic Cancer through
    Sasaki N; Hirano K; Shichi Y; Gomi F; Yoshimura H; Matsushita A; Toyoda M; Ishiwata T
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
    Thakur PC; Miller-Ocuin JL; Nguyen K; Matsuda R; Singhi AD; Zeh HJ; Bahary N
    J Transl Med; 2018 Jul; 16(1):190. PubMed ID: 29986726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
    Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
    J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
    Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM
    World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
    Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
    J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth.
    Khan HY; Mpilla GB; Sexton R; Viswanadha S; Penmetsa KV; Aboukameel A; Diab M; Kamgar M; Al-Hallak MN; Szlaczky M; Tesfaye A; Kim S; Philip PA; Mohammad RM; Azmi AS
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32235707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.